BOLD Innovation that Matters! - May 2023 Emerging Innovators

Here we’ll bring you 10 innovative biotech companies that have drawn significant Series A and Series B investments in May 2023, showcasing BOLD solutions for patients globally.

1. ReNAgade Therapeutics : aiming to address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body. ($300M Series A)
2. Ray Therapeutics, Inc. : developing novel optogenetics gene therapies to restore vision, independent of genetic mutation for patients with inherited retinal diseases. ($100M Series A)
3. COHERENT BIOPHARMA (SUZHOU) CO., LTD. : using bi-targeting XDC technology to actively and cell/tissue-specifically deliver any bioactive molecule, overcoming the undruggability obstacle of a variety of molecules with high bioactivity. (~$100M Series B/B+)
4. Convergent Therapeutics, Inc. : developing next-generation radiopharmaceutical therapies for prostate and other cancers. ($90M Series A)
5. Nido Biosciences : leveraging advancements in the understanding of human genetics and disease to develop precision medicines that address the fundamental biology of disease and restore healthy cell function. ($109M combined Series Seed, A and B)
6. Initial Therapeutics : selectively modulating translation of pathogenic proteins in the exit tunnel of the ribosome, when the proteins are in their linear sequence stage and before they are fully formed, makes possible a new kind of therapeutic with the potential to stop disease processes in their initial, earliest stages. ($75M Series A)
7. Ensoma : aiming to target and reprogram both immune cells and self-renewing hematopoietic stem cells, can create multicellular and multigenic medicines that solve potency and durability challenges limiting current approaches. ($50M Series B extension)
8. ARTHEx Biotech : developing innovative medicines through the modulation of microRNAs. (€42M Series B)
9. Dualyx : developing novel Treg based therapies to address the needs of patients with difficult-to-treat autoimmune diseases. (€40M Series A)
10. NewLimit : building a novel platform to discover epigenetic reprogramming therapies at industrial scale. ($40M Series A)